首页> 外文学位 >Kinetic characterization of protein arginine deiminase 4: An enzyme dysregulated in rheumatoid arthritis.
【24h】

Kinetic characterization of protein arginine deiminase 4: An enzyme dysregulated in rheumatoid arthritis.

机译:精氨酸脱亚氨酶4的动力学表征:类风湿关节炎中失调的一种酶。

获取原文
获取原文并翻译 | 示例

摘要

Modern drug discovery is a rigorous multi-step process starting from target identification to the synthesis of lead compounds and their pharmacological validation as drugs in model systems. Enzymes have emerged as the most attractive targets for drug intervention, given their essential catalytic roles in numerous biological pathways as well as their unique conformation which lends itself to external manipulation. Typically, this is achieved through small molecules or peptides that exploit the structural features of a substrate or cofactor or product in order to create a moiety with very high binding affinity for the enzyme. The design of such small molecules as chemical tools to perturb biological systems has offered a facile way of deconstructing the cellular roles of several enzymes and in providing a working scaffold for designing potent drugs in the future. This work describes some initial attempts to characterize an enzyme Protein Arginine Deiminase 4 or PAD4, using methods in enzymology, chemistry and biology. PAD4 is implicated in a joint disease called Rheumatoid arthritis (RA), a disease that is incurable, despite several decades of clinical efforts. Targeting RA via PAD4 would require a detailed understanding of its enzymatic properties and cellular functions, which have so far remained poorly understood. Emerging data suggests that the important role of PAD4 in RA as well as in normal physiology may be mediated, at least in part, through its role in transcriptional regulation and apoptosis. It is hoped that our studies on characterizing the various aspects of PAD4, including catalysis and regulation, would add to this knowledge and aid in the design of specific small molecule drugs for PAD4 that may find a use as anti-RA therapeutics.
机译:现代药物发现是一个严格的多步骤过程,从目标识别到先导化合物的合成及其在模型系统中作为药物的药理验证开始。酶已成为药物干预的最有吸引力的靶标,这是因为它们在众多生物途径中的重要催化作用以及独特的构象,使其易于进行外部操纵。通常,这是通过利用底物或辅因子或产物的结构特征的小分子或肽来实现的,以产生对酶具有很高结合亲和力的部分。这种小分子的设计,如扰乱生物系统的化学工具,提供了一种简便的方法来解构几种酶的细胞作用,并为将来设计有效药物提供了可行的支架。这项工作描述了使用酶学,化学和生物学方法表征蛋白精氨酸脱亚氨酶4或PAD4的一些初步尝试。尽管有数十年的临床努力,但PAD4与一种称为类风湿性关节炎(RA)的关节疾病有关,这种疾病是无法治愈的。通过PAD4靶向RA需要对其酶学性质和细胞功能进行详细的了解,到目前为止,人们对其了解还很少。新兴数据表明,PAD4在RA和正常生理中的重要作用可能至少部分地通过其在转录调节和细胞凋亡中的作用介导。希望我们对表征PAD4各个方面(包括催化和调节)的研究将增加这一知识,并有助于设计用于PAD4的特定小分子药物,这些药物可能会用作抗RA治疗药物。

著录项

  • 作者

    Bhatia, Monica.;

  • 作者单位

    University of South Carolina.;

  • 授予单位 University of South Carolina.;
  • 学科 Chemistry Biochemistry.
  • 学位 Ph.D.
  • 年度 2007
  • 页码 133 p.
  • 总页数 133
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 生物化学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号